Active, not recruitingPhase 3NCT05270837
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
Studying Phenylketonuria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Principal Investigator
- Study DirectorBioMarin Pharmaceutical
- Intervention
- Pegvaliase(drug)
- Enrollment
- 55 enrolled
- Eligibility
- 12-17 years · All sexes
- Timeline
- 2022 – 2025
Study locations (16)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- University of South Florida, Tampa, Florida, United States
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- IU Health University Hospital, Indianapolis, Indiana, United States
- University of Kentucky College of Medicine, Lexington, Kentucky, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
- University of Utah Medical Center, Salt Lake City, Utah, United States
- University of Virginia School of Medicine, Charlottesville, Virginia, United States
- Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
- Charité - Universitätsmedizin Berlin, Berlin, Germany
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05270837 on ClinicalTrials.govOther trials for Phenylketonuria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06971731A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)Otsuka Pharmaceutical Development & Commercialization, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT07255599Evaluation of BH4 Responsiveness in Our PKU PatientsSohag University
- RECRUITINGNANCT06941532GMP Powdered Substitutes in PKU and TYRNutricia UK Ltd
- ENROLLING BY INVITATIONNANCT06940193A Self-test Home-use Blood Phenylalanine Monitoring System Under the Brand Name Egoo Phe System Has Been Developed for Measurement of Phenylalanine (Phe) in Individuals Diagnosed With Phenylketonuria (PKU): The Study Purpose is to Evaluate Accuracy and UsabilityEgoo Health Aps
- ACTIVE NOT RECRUITINGPHASE4NCT06901323Effect of L-carnitine Supplementation on Phenylalanine and Brain-derived Neurotrophic Factor Levels in Infants and Children With PhenylketonuriaMansoura University
- RECRUITINGNANCT06969209Brain Aging in PhenylketonuriaInsel Gruppe AG, University Hospital Bern
- RECRUITINGPHASE1NCT06332807AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)NGGT INC.
- RECRUITINGNANCT06560736Development of Novel Psychological Assessment Tools and Anxiety Intervention for PhenylketonuriaUniversity of Missouri-Columbia